Boston Scientific Corp

Company facts

Industry

Surgical & Medical Instruments & Apparatus

Headquarters

Marlborough, Massachusetts

Most recent report

10-Q, filed Nov 2, 2026

Incorporated

Delaware

Filings on record

1,003+ filings

On EDGAR

CIK 885725

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 10 sections worth reading, with 0 positive, 7 notable, and 5 negative flags.

• Financial Statements (Item 1)

  Financial statements and notes: large acquisition, debt, litigation, restructuring, cash burn.
  Notable

  • Pending $14.5B Penumbra acquisition; $6.0B term loan and $2.0B revolver arranged; FTC second request received.
  • Leverage ratio 1.95x vs 3.75x covenant; $1.128B of $1.160B litigation exclusion still available.
  • Discrete tax benefit of $383M in first nine months 2026 cut reported tax rate to 4.5% from 17.2%.
  • New $700-800M restructuring plan approved July 2026; $102M incurred so far, expects $500M annual savings.
  Negative

  • Securities class action and four derivative suits filed in 2026; litigation accrual rose to $370M from $242M.

• Management's Discussion (Item 2)

  Cybersecurity incident materially hit Q3 2026 results; $14.5B Penumbra acquisition pending; new $700-800M restructuring plan.
  Notable

  • Entered agreement with Blackstone for up to $455M to co-fund VITALYST circulatory support system development.
  • Board approved $4B increase to share repurchase authorization; $2B ASR completed in Q2 2026; $3B remaining.
  Negative

  • Cybersecurity incident caused significant disruption, materially impacting Q3 2026 financial results.

• Risk Factors (Item 1A)

  Quantifies a real August 2026 cyber incident that materially hit Q3 2026 results and triggered lawsuits.
  Notable

  • Expects increased expenses for response, remediation, and strengthening cybersecurity program going forward.
  Negative

  • Cyber incident on Aug 25, 2026 caused global disruption, materially hit Q3 2026 results, and triggered civil lawsuits.
  • Civil legal claims have been filed; regulatory scrutiny possible; outcome and timeline unknown.
  • May not recover all impacted revenue; potential loss of market share and other adverse impacts remain.

What changed: Sep 2026 vs. Jun 2026

About 9% of BSX's Sep 2026 10-Q is new information. 30 paragraphs were added, 154 changed, and 34 removed. Below are the most important lines SECSift identified.

• Item 1 63
• Item 2 39
• Item 1A 8
• Item 3 3
• Item 4 3
• Item 6 2
• Item 5 1